Tevogen Inc. — Form SCHEDULE 13D/A
Filed November 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 78/100
What the filing says
On November 2, 2026, Ryan Saadi received a restricted stock award of 50,000,000 shares under Tevogen's 2024 Omnibus Incentive Plan. All shares vest in full only upon written Committee certification (by the due date of the 2031 annual report) that the company achieved $1 billion in aggregate revenue during 2026–2031. If the revenue threshold is not met by December 31, 2031, all 50 million shares are forfeited with no consideration. The award includes standard clawback, forfeiture, and conduct restrictions.
Why this rating
50M shares at ~$63.7M market cap is ~78% of current equity outstanding—massive dilution IF vested. However, achievement contingency ($1B revenue threshold) makes vesting uncertain and distant (5 years). Material for current shareholders' ownership but speculative; depends entirely on undisclosed revenue baseline and growth trajectory.
Price action (we called it neutral)
before filing · preread $0.09 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.